Requests the Food and Drug Administration (FDA) to take the following actions to accelerate access to Pritelivir, an investigational treatment for Herpes Simplex Virus (HSV) patients. 1. Grant Expanded Access (Compassionate Use) to Pritelivir under the existing Expanded Access Programs (EAP) to allow patients with severe or refractory HSV infections access to the drug.